Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center

(2017) Blanca Sanchez-Gonzalez et al.   LEUKEMIA & LYMPHOMA

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

(2017) Pieternella Lugtenburg et al.   HAEMATOLOGICA

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

(2017) Andrew Davies et al.   Lancet Haematology

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) M. Dreyling et al.   ANNALS OF ONCOLOGY

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

(2016) Erwin De Cock et al.   PLoS One

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study

(2014) Antonio Salar et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

(2014) Andrew Davies et al.   LANCET ONCOLOGY

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

(2013) O Shpilberg et al.   BRITISH JOURNAL OF CANCER

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY